Biomarkers for depression and methods using the same
View Patent ↗The present invention provides various biomarkers of depression. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of depression, methods of determining predisposition to depression, methods of monitoring progression/regression of depression, methods of assessing efficacy of compositions for treating depression, methods of screening compositions for activity in modulating biomarkers of depression, methods of treating depression, as well as other methods based on biomarkers of depression.
1. A method of aiding in diagnosing whether a subject has depression, comprising:
analyzing a blood sample that was removed from a subject to determine the level(s) of biomarkers for depression in the sample, wherein the biomarkers comprise 3-hydroxybutanoic acid, alpha-hydroxyisobutyric acid, and 4-aminobutanoic acid, and wherein the analysis method for the blood sample is mass spectrometry; and
comparing the level(s) of the biomarkers in the sample to depression-positive and/or depression-negative reference levels of the biomarkers in order to diagnose whether the subject has depression.
2. The method of claim 1 , wherein the depression-negative reference levels of the biomarkers comprise levels of the biomarkers in one or more samples from one or more subjects not having depression and the depression-positive reference levels of the biomarkers comprise levels of the biomarkers in one or more samples from one or more subjects diagnosed with depression.
3. The method of claim 2 , wherein differential levels of the biomarkers between the sample and the depression-negative reference levels are indicative of a diagnosis of depression in the subject.
4. The method of claim 2 , wherein differential levels of the biomarkers between the sample and the depression-positive reference levels are indicative of a diagnosis of no depression in the subject.
5. The method of claim 2 , wherein levels of the biomarkers in the sample corresponding to the depression-positive reference levels are indicative of a diagnosis of depression in the subject.
6. The method of claim 2 , wherein levels of the biomarkers in the sample corresponding to the depression-negative reference levels are indicative of a diagnosis of no depression in the subject.
7. The method of claim 1 , wherein the biological sample is blood plasma.
8. The method of claim 1 , wherein the biomarkers further comprise one or more biomarkers selected from the group consisting of glycerol and one or more fatty acids.
9. The method of claim 8 , wherein the fatty acids are selected from the group consisting of stearate, myristate, linoleate, palmitoleate, oleate, palmitate, and pentadecanoate.
10. A method of monitoring progression/regression of depression in a subject comprising:
analyzing a first biological sample that was removed from a subject to determine the level(s) of biomarkers for depression in the sample, wherein the biomarkers comprise 3-hydroxybutanoic acid and 4-aminobutanoic acid and the first sample is obtained from the subject at a first time point, and wherein the analysis method for the blood sample is mass spectrometry;
analyzing a second biological sample that was removed from a subject to determine the level(s) of the biomarkers, wherein the second sample is obtained from the subject at a second time point and wherein the analysis method is mass spectrometry; and
comparing the level(s) of the biomarkers in the first sample to the level(s) of the biomarkers in the second sample in order to monitor the progression/regression of depression in the subject.
11. The method of claim 10 , wherein the method further comprises comparing the level(s) of the biomarkers in the first sample, the level(s) of the biomarkers in the second sample, and/or the results of the comparison of the level(s) of the biomarkers in the first and second samples to depression-positive reference levels, depression-negative reference levels, depression-progression-positive reference levels, and/or depression-regression-positive reference levels of the biomarkers.
12. The method of claim 10 , wherein the biomarkers further comprise one or more biomarkers selected from the group consisting of glycerol and one or more fatty acids.
13. The method of claim 12 , wherein the fatty acids are selected from the group consisting of stearate, myristate, linoleate, palmitoleate, oleate, palmitate, and pentadecanoate.
14. A method of assessing the efficacy of a composition for treating depression comprising:
analyzing a blood sample removed from a subject having depression and currently or previously being treated with a composition to determine the level(s) of biomarkers for depression, wherein the biomarkers comprise 3-hydroxybutanoic acid and 4-aminobutanoic acid and wherein the analysis method for the blood sample is mass spectrometry; and
comparing the level(s) of the biomarkers in the sample to (a) levels of the biomarkers in a previously-taken biological sample from the subject, wherein the previously-taken biological sample was obtained from the subject before being treated with the composition, (b) depression-positive reference levels of the biomarkers, (c) depression-negative reference levels of the biomarkers, (d) depression-progression-positive reference levels of the biomarkers, and/or (e) depression-regression-positive reference levels of the biomarkers.
15. The method of claim 14 , wherein the biomarkers further comprise one or more biomarkers selected from the group consisting of glycerol and one or more fatty acids.
16. The method of claim 15 , wherein the fatty acids are selected from the group consisting of stearate, myristate, linoleate, palmitoleate, oleate, palmitate, and pentadecanoate.
17. A method for assessing the efficacy of a composition in treating depression, comprising:
analyzing a first blood sample obtained from a subject to determine the level(s) of biomarkers for depression, the first sample obtained from the subject at a first time point, wherein the biomarkers comprise 3-hydroxybutanoic acid and 4-aminobutanoic acid and wherein the analysis method for the blood sample is mass spectrometry;
administering the composition to the subject;
analyzing a second biological sample obtained from the subject to determine the level(s) of the biomarkers, wherein the second sample is obtained from the subject at a second time point after administration of the composition and wherein the analysis method is mass spectrometry; and
comparing the level(s) of the biomarkers in the first sample to the level(s) of the biomarkers in the second sample in order to assess the efficacy of the composition for treating depression.
18. The method of claim 17 , wherein the biomarkers further comprise one or more biomarkers selected from the group consisting of glycerol and one or more fatty acids.